• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
High purity nutritional supplement R-lipoic acid powder
Alpha lipoic acid powder
Chromloong
Alphasil Columns
AlphaHybrid Columns
Marsil Columns

Indoco gets USFDA nod for apixaban tablets

expresspharmaSeptember 15, 2020

Tag: Indoco , FDA , apixaban tablets

Indoco Remedies announced receipt of approval for its ANDA for Apixaban Tablets 2.5 mg and 5 mg. The products are therapeutically equivalent to the Reference Listed Drug ‘Eliquis’ of Bristol-Myers Squibb (BMS).

Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.

The US market size of Apixaban Tablets is $11,037 million as per IMS MAT June’20 data.

Commenting on this development, Aditi Kare Panandikar, MD, Indoco Remedies said, “The receipt of approval from the US health regulator for the generic version of Apixaban Tablets is encouraging.”

Previous:Saptagir Labs signs manufacturing deal with Jubilant Generics for remdesivir

Next:Pfizer CentreOne Appoints General Manager

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Indoco gets USFDA nod for apixaban tablets | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Ribavirin (FDA)

Ribavirin (FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Simvastatin (FDA)

Simvastatin (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Fosphenytoin sodium (FDA)

Fosphenytoin sodium (FDA)
Sirolimus (FDA)

Sirolimus (FDA)
Hexafluorodianhydride(6-FDA)

Hexafluorodianhydride(6-FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service